Gene · 3020
Papers2,385
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,385
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Contribution of histone variants to aneuploidy: a cancer perspective. | Front Genet | 2023 | 38075697 | PubTator, text mining | PubMed |
| Towards Cancer Nanoradiopharmaceuticals-Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels. | Cancers (Basel) | 2023 | 38067350 | PubTator, text mining | PubMed |
| Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies. | Genome Biol | 2023 | 38066546 | PubTator, text mining | PubMed |
| A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation. | Acta Neuropathol | 2023 | 38066305 | PubTator, text mining | PubMed |
| Current indications for denosumab in benign bone tumours. | EFORT Open Rev | 2023 | 38038377 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| Advances in Glioblastoma Therapy: An Update on Current Approaches. | Brain Sci | 2023 | 38002496 | PubTator, text mining | PubMed |
| From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients. | Biomedicines | 2023 | 38001908 | PubTator, text mining | PubMed |
| Chemotherapy in pediatric brain tumor and the challenge of the blood-brain barrier. | Cancer Med | 2023 | 37997517 | PubTator, text mining | PubMed |
| [Giant cell tumor of bone-an update]. | Pathologie (Heidelb) | 2023 | 37985483 | PubTator, text mining | PubMed |
| Adult cerebral high-grade glioneuronal tumor with perivascular or pseudopapillary growth co-existing with low-grade tumor: a case report. | Int J Clin Exp Pathol | 2023 | 37970335 | PubTator, text mining | PubMed |
| Inhibition of exosome biogenesis affects cell motility in heterogeneous sub-populations of paediatric-type diffuse high-grade gliomas. | Cell Biosci | 2023 | 37957701 | PubTator, text mining | PubMed |
| Brainstem tumors in children: a monocentric series in the light of genetic and bio-molecular progress in pediatric neuro-oncology. | Front Pediatr | 2023 | 37936887 | PubTator, text mining | PubMed |
| Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study. | Elife | 2023 | 37929934 | PubTator, text mining | PubMed |
| MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice. | Acta Neuropathol Commun | 2023 | 37919824 | PubTator, text mining | PubMed |
| Management of a rare mandibular giant cell tumor of bone by neoadjuvant denosumab therapy and surgery: A 4-year follow-up case report. | Int J Surg Case Rep | 2023 | 37913666 | PubTator, text mining | PubMed |
| Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospects. | Front Mol Biosci | 2023 | 37908227 | PubTator, text mining | PubMed |
| Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration. | Brain Sci | 2023 | 37891850 | PubTator, text mining | PubMed |
| Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review. | Curr Oncol | 2023 | 37887575 | PubTator, text mining | PubMed |
| VRK3 depletion induces cell cycle arrest and metabolic reprogramming of pontine diffuse midline glioma - H3K27 altered cells. | Front Oncol | 2023 | 37886173 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3020/papers?page=10